Analysts expect a good set of numbers for Biocon with revenue growth of 35 percent, EBITDA up around 76 percent and margins at 26 percent. The Bengaluru-based biopharma company will report its March-quarter earnings on Thursday.
The company is expected to report profit growth of around 44 percent supported by better margins, which are expected to grow by about 25 percent. Growth in biosimilars will be led by launches and sales in emerging markets.
Syngene, the research and development (R&D) arm of Biocon, came out with numbers where the revenue growth is 30 percent, margins are 30 percent. Syngene has recorded profits of around Rs 100 crore for the first time ever. So it has been a brilliant set of numbers and that will be incorporated into Biocon numbers as well.